# MNOV catalysts: MEDICINOVA INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mnov/catalysts

> MEDICINOVA INC (MNOV) has 4 upcoming catalysts. The next is the MN-001 topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | MEDICINOVA INC |
| Ticker | MNOV (Nasdaq) |
| SEC CIK | 1226616 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mnov |

## Cash runway

Cash $29.3M as of 2026-09-30; quarterly burn $2.4M; about 36.8 months of runway at that rate (XBRL company facts, accession 0001193125-26-458562).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2022 | [Ibudilast topline data readout](https://sec-api.dev/pdufa/ibudilast) | MNOV |  | completed, positive | "In June 2022, we announced positive top-line results from this Phase 2 clinical trial in which MN-166 (ibudilast) demonstrated large improvements compared to placebo for all four clinical endpoints analyzed." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1226616/000095017024126343/mnov-20240930.htm)) |
| Dec 2026 to Mar 2027 | [MN-001 topline data readout](https://sec-api.dev/pdufa/mn-001) | MNOV | Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease | scheduled | "NCT05464784 (MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor MediciNova." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05464784)) |
| December 2026 | [MN-001 primary completion](https://sec-api.dev/pdufa/mn-001) | MNOV | Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease | scheduled | "NCT05464784 (MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor MediciNova." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05464784)) |
| April 2027 | [Ibudilast primary completion](https://sec-api.dev/pdufa/ibudilast) | MNOV | Amyotrophic Lateral Sclerosis | scheduled | "NCT04057898 (Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor MediciNova." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04057898)) |
| Apr to Jul 2027 | [Ibudilast topline data readout](https://sec-api.dev/pdufa/ibudilast) | MNOV | Amyotrophic Lateral Sclerosis | scheduled | "NCT04057898 (Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor MediciNova." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04057898)) |

## Drugs

- [Ibudilast](https://sec-api.dev/pdufa/ibudilast): Amyotrophic Lateral Sclerosis
- [MN-001](https://sec-api.dev/pdufa/mn-001): Diabetes Mellitus, Type 2

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mnov/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MNOV catalysts: MEDICINOVA INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mnov/catalysts

```bibtex
@misc{secapidev_companies_mnov_catalysts_20261116,
  title        = {MNOV catalysts: MEDICINOVA INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mnov/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mnov_catalysts_20261116","title":"MNOV catalysts: MEDICINOVA INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mnov/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
